Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes

[1] Larsson SC(2007)Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 856-862

[2] Mantzoros CS(2009)Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006 Diabetologia 52 240-246

[3] Wolk A(2011)Intracellular insulin in human tumors: examples and implications Diabetol Metab Syndr 3 5-709

[4] Tseng CH(2011)IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer Endocr Relat Cancer 18 699-951

[5] Chong CK(2010)Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes Endocr Relat Cancer 17 941-2710

[6] Tai TY(2009)Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer Int J Cancer 125 2704-1005

[7] Radulescu RT(2000)Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 999-165

[8] Dool CJ(2010)Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research Postgrad Med 122 158-523

[9] Mashhedi H(2011)Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation Horm Metab Res 43 519-2003

[10] Zakikhani M(2010)Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 33 1997-2262

[1] Larsson SC(2007)Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 856-862

[2] Mantzoros CS(2009)Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006 Diabetologia 52 240-246

[3] Wolk A(2011)Intracellular insulin in human tumors: examples and implications Diabetol Metab Syndr 3 5-709

[4] Tseng CH(2011)IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer Endocr Relat Cancer 18 699-951

[5] Chong CK(2010)Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes Endocr Relat Cancer 17 941-2710

[6] Tai TY(2009)Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer Int J Cancer 125 2704-1005

[7] Radulescu RT(2000)Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 999-165

[8] Dool CJ(2010)Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research Postgrad Med 122 158-523

[9] Mashhedi H(2011)Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation Horm Metab Res 43 519-2003

[10] Zakikhani M(2010)Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 33 1997-2262